Clinical pharmacology of topiramate in migraine prevention

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 9, 2011, Pages 1169-1181

  Ferrari, Anna ^a   Tiraferri, Ilaria ^b   Neri, Laura ^b   Sternieri, Emilio ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Chronic migraine; Medication overuse; Migraine; Prophylaxis; Topiramate

Indexed keywords

ALMOTRIPTAN; AMITRIPTYLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CARBAMAZEPINE; CARBONATE DEHYDRATASE INHIBITOR; DIAZEPAM; DIGOXIN; DIHYDROERGOTAMINE; ETHINYLESTRADIOL; FLUNARIZINE; GLIBENCLAMIDE; HISTAMINE; IMIPRAMINE; LAMOTRIGINE; LITHIUM; METFORMIN; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PROPRANOLOL; RISPERIDONE; SUMATRIPTAN; TOPIRAMATE; VALPROIC ACID;

ANOREXIA; BLURRED VISION; BREAST FEEDING; CLEFT LIP; CONCENTRATION LOSS; CONGENITAL MALFORMATION; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; GLAUCOMA; HUMAN; HYPOSPADIAS; INSOMNIA; MEDLINE; MEMORY DISORDER; METABOLIC ACIDOSIS; MIGRAINE; NAUSEA; NEPHROLITHIASIS; NEUROMODULATION; PARESTHESIA; PREGNANCY; REVIEW; SIDE EFFECT; SOMNOLENCE; TASTE DISORDER; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

ANTICONVULSANTS; DRUG INTERACTIONS; DRUG TOXICITY; FRUCTOSE; HUMANS; MIGRAINE DISORDERS; TIME FACTORS;

EID: 80051905708     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.602067     Document Type: Review

References (101)

1. Jensen R, Stovner LJ Epidemiology and comorbidity of headache. Lancet Neurol 2008;7:354-61 An excellent review about epidemiology and co-morbidity of headache.
2. Headache classification subcommittee of the international headache society. The international classification of headache disorders, 2nd edition. Cephalalgia 2004;7(Suppl 1):9-160 An indispensable instrument for the diagnosis of headache disorders.
3. Stovner L, Hagen K, Jensen R, et al. The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27:193-210 An extensive review about the burden of headache.
4. Lipton RB, Bigal ME. Migraine: Epidemiology, impact, and risk factors for progression. Headache 2005;45(Suppl 1):3-13
5. Diener HC, Holle D, Dodick D. Treatment of chronic migraine. Curr Pain Headache Rep 2011;15:64-9 A comprehensive review about chronic migraine care.
6. Pascual J, Colas R, Castillo J. Epidemiology of chronic daily headache. Curr Pain Headache Pain Rep 2001;5:529-36
7. Welch KM. Brain hyperexcitability: The basis for antiepileptic drugs in migraine prevention. Headache 2005;45(Suppl 1):S25-32
8. Ramadan NM, Buchanan TM. New and future migraine therapy. Pharmacol Ther 2006;112:199-212
9. Tepper SJ. The role of prevention. Handb Clin Neurol 2010;97:195-205
10. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol 2009;16:968-81
11. Brandes JL. Practical use of topiramate for migraine prevention. Headache 2005;45(Suppl 1):66-73
12. Adelman JU, Adelman RD. Current options for prevention and treatment of migraine. Clin Ther 2001;23:772-88
13. Loder E, Biondi D. General principles of migraine management: The changing role of prevention. Headache 2005;45(Suppl 1):33-47
14. Edvinsson L, Linde M. New drugs in migraine treatment and prophylaxis: Telcagepant and topiramate. Lancet 2010;376:645-55 A comprehensive review about new drugs for migraine treatment.
15. Meurs A, Clinckers R, Ebinger G, et al. Substantia nigra is an anticonvulsant site of action of topiramate in the focal pilocarpine model of limbic seizures. Epilepsia 2006;47:1519-35
16. Pappagallo M. Newer antiepileptic drugs: Possible uses in the treatment of neuropathic pain and migraine. Clin Ther 2003;25:2506-38
17. Calabresi P, Galletti F, Rossi C, et al. Antiepileptic drugs in migraine: From clinical aspects to cellular mechanisms. Trends Pharmacol Sci 2007;28:188-95 A comprehensive review about new antiepileptics for migraine treatment.
18. Mc Lean MJ, Bukhari AA, Wamil AW. Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia 2000;41(Suppl 1):21-4
19. Zhang X, Velumian AA, Jones OT, et al. Modulation of high-voltage- activated calcium channels in dentate granule cells by topiramate. Epilepsia 2000;41(Suppl 1):52-60
20. Kaminski RM, Banerjee M, Rogawski MA. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 2004;46:1097-104
21. White HS. Molecular pharmacology of topiramate: Managing seizures and preventing migraine. Headache 2005;45(Suppl 1):48-56
22. White HS, Brown SD, Woodhead JH, et al. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 2000;41(Suppl 1):17-20
23. Herrero AI, Del Olmo N, Gonzalez-Escalada JR, et al. Two new actions of topiramate: Inhibition of depolarizing GABA(A) mediated responses and activation of a potassium conductance. Neuropharmacology 2002;42:210-20
24. Pasternack M, Voipio J, Kaila K. Intracellular carbonic anhydrase activity and its role in GABA-induced acidosis in isolated rat hippocampal pyramidal neurons. Acta Physiol Scand 1993;148:229-31
25. Britzi M, Perucca E, Soback S, et al. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia 2005;46:378-84
26. Doose DR, Walker SA, Gisclon LG, Nayak RK. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol 1996;36:884-91
27. Johannessen SI. Pharmacokinetics and interaction profile of topiramate: Review and comparison with other newer antiepileptic drugs. Epilepsia 1997;38(Suppl 1):S18-23 An extensive review about pharmacokinetics of topiramate.
28. Christensen J, Hojskov CS, Dam M, Poulsen JH. Plasma concentration of topiramate correlates with cerebrospinal fluid concentration. Ther Drug Monit 2001;23:529-35
29. Ohman I, Vitols S, Luef G, et al. Topiramate kinetics during delivery, lactation, and in the neonate: Preliminary observations. Epilepsia 2002;43:1157-60
30. Sachdeo RC, Sachdeo SK, Walker SA, et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996;37:774-80
31. Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet 1996;31:29-46
32. Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004;12:763-80 An excellent review about pharmacokinetic interactions of topiramate.
33. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: A double-blind, placebo-controlled study. Headache 2001;41:968-75
34. Martinez HR, Londono O, Cantu-Martinez L, et al. Topiramate as an adjunctive treatment in migraine prophylaxis. Headache 2003;43:1080-4
35. Edwards KR, Potter DL, Wu SC, et al. Topiramate in the preventive treatment of episodic migraine: A combined analysis from pilot, double-blind, placebo-controlled trials. CNS Spectr 2003;8:428-32
36. Mei D, Capuano A, Vollono C, et al. Topiramate in migraine prophylaxis: A randomised double-blind versus placebo study. Neurol Sci 2004;25:245-50
37. Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol 2004;61:490-5
38. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: A randomized controlled trial. JAMA 2004;291:965-73
39. Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis-results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004;251:943-50
40. Bussone G, Diener HC, Pfeil J, Schwalen S. Topiramate 100 mg/day in migraine prevention: A pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 2005;59:961-8
41. Freitag FG, Forde G, Neto W, et al. Analysis of pooled data from two pivotal controlled trials on the efficacy of topiramate in the prevention of migraine. J Am Osteopath Assoc 2007;107:251-8
42. Lo YL, Lum SY, Fook-Chong S, Siow HC. A pilot study of topiramate dosages for migraine prophylaxis in an Asian population. J Headache Pain 2010;11:175-8
43. Rapoport A, Mauskop A, Diener HC, et al. Long-term migraine prevention with topiramate: Open-label extension of pivotal trials. Headache 2006;46:1151-60
44. Diener HC, Agosti R, Allais G, et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): A randomised, double-blind, placebo-controlled trial. Lancet Neurol 2007;6:1054-62
45. Schoenen J, Reuter U, Diener HC, et al. Factors predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate. Cephalalgia 2010;30:1290-5
46. Limmroth V, Biondi D, Pfeil J, Schwalen S. Topiramate in patients with episodic migraine: Reducing the risk for chronic forms of headache. Headache 2007;47:13-21
47. Lipton RB, Silberstein S, Dodick D, et al. Topiramate intervention to prevent transformation of episodic migraine: The topiramate INTREPID study. Cephalalgia 2011;31:18-30
48. Allais G, Sanchez Del Rio M, Diener HC, et al. Perimenstrual migraines and their response to preventive therapy with topiramate. Cephalalgia 2011;31:152-60
49. Cutrer FM. Antiepileptic drugs: How they work in headache. Headache 2001;41(Suppl 1):3-10
50. Lampl C, Bonelli S, Ransmayr G. Efficacy of topiramate in migraine aura prophylaxis: Preliminary results of 12 patients. Headache 2004;44:174-6
51. Reuter U, Del Rio MS, Diener HC, et al. Migraines with and without aura and their response to preventive therapy with topiramate. Cephalalgia 2010;30:543-51
52. Nelles G, Delbruck A, Schulze L, et al. Topiramate for migraine prevention in a naturalistic setting: Results from an open label, flexible dose study. Headache 2009;49:1454-65
53. Malessa R, Gendolla A, Steinberg B, et al. Prevention of episodic migraine with topiramate: A prospective 24-week, open-label, flexible-dose clinical trial with optional 24 weeks follow-up in a community setting. Curr Med Res Opin 2010;26:1119-29
54. Becker WJ, Christie SN, Ledoux S, Binder C. Topiramate prophylaxis and response to triptan treatment for acute migraine. Headache 2006;46:1424-30
55. Bermejo PE, Dorado R, Gomez-Arguelles JM. Variation in almotriptan effectiveness according to different prophylactic treatment. Headache 2009;49:1277-82
56. Gracia-Naya M, Latorre-Jimenez AM. Topiramate or flunarizine in the preventive treatment of migraine. A comparative study of two series of cases. Rev Neurol 2005;41:705-8
57. Shaygannejad V, Janghorbani M, Ghorbani A, et al. Comparison of the effect of topiramate and sodium valproate in migraine prevention: A randomized blinded crossover study. Headache 2006;46:642-8
58. Ashtari F, Shaygannejad V, Akbari M. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand 2008;118:301-5
59. Gupta P, Singh S, Goyal V, et al. Low-dose topiramate versus lamotrigine in migraine prophylaxis (The Lotolamp Study). Headache 2007;47:402-12
60. Millan-Guerrero RO, Isais-Millan R, Barreto-Vizcaino S, et al. Subcutaneous histamine versus topiramate in migraine prophylaxis: A double-blind study. Eur Neurol 2008;59:237-42
61. Dodick DW, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: A 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009;31:542-59
62. Pascual J, Rivas MT, Leira R. Testing the combination beta-blocker plus topiramate in refractory migraine. Acta Neurol Scand 2007;115:81-3
63. Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg 2008;110:979-84
64. Silvestrini M, Bartolini M, Coccia M, et al. Topiramate in the treatment of chronic migraine. Cephalalgia 2003;23:820-4
65. Peres MF, Mercante JP, Tanuri FC, et al. Chronic migraine prevention with topiramate. J Headache Pain 2006;7:185-7
66. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial. Headache 2007;47:170-80
67. Diener HC, Bussone G, Van Oene J, et al. Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia 2007;27:814-23
68. Rothrock JF, Parada VA, Drinkard R, et al. Predictors of a negative response to topiramate therapy in patients with chronic migraine. Headache 2005;45:932-5
69. Bartolini M, Silvestrini M, Taffi R, et al. Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol 2005;28:277-9
70. Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: A pilot study. Headache 2009;49:1466-78
71. Cady RK, Schreiber CP, Porter JA, et al. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache 2011;51:21-32
72. Valguarnera F, Tanganelli P. The efficacy of withdrawal therapy in subjects with chronic daily headache and medication overuse following prophylaxis with topiramate and amitriptyline. Neurol Sci 2010;31(Suppl 1):S175-7
73. Adelman J, Freitag FG, Lainez M, et al. Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials. Pain Med 2008;9:175-85
74. Luykx J, Mason M, Ferrari MD, Carpay J. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther 2009;85:283-8 An interesting comparison of topiramate-related adverse reaction between epilepsy and migraine.
75. Lee ST, Chu K, Park JE, et al. Paresthesia as a favorable predictor of migraine prophylaxis using topiramate. Eur J Neurol 2007;14:654-8
76. Luykx JJ, Carpay JA. Nervous system adverse responses to topiramate in the treatment of neuropsychiatric disorders. Expert Opin Drug Saf 2010;9:623-31 A state-of-the art study about nervous system adverse responses to topiramate.
77. Andrade C, Bhakta SG, Fernandes PP. Familial vulnerability to an unusual cognitive adverse effect of topiramate: Discussion of mechanisms. Indian J Psychiatry 2010;52:260-3
78. Mirza N, Marson AG, Pirmohamed M. Effect of topiramate on acid-base balance: Extent, mechanism and effects. Br J Clin Pharmacol 2009;68:655-61 A state-of-the art study about effect of topiramate on acid-base balance.
79. Maalouf NM, Langston JP, Van Ness PC. Nephrolithiasis in topiramate users. Urol Res 2010;published on line 17 December 2010; doi:10.1007/s00240-010- 0347-5
80. Natesh S, Rajashekhara SK, Rao ASD, Shetty B. Topiramate-induced angle-closure with acute myopia, macular striae. Oman J Ophthalmol 2010;3:26-8
81. Markowitz SY, Robbins MS, Cascella C, et al. Reversible hypohidrosis with topiramate therapy for chronic migraine. Headache 2010;50:672-4
82. Hunt S, Russell A, Smithson WH, et al. Topiramate in pregnancy: Preliminary experience from the UK epilepsy and pregnancy register. Neurology 2008;71:272-6
83. Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: A review of human studies. Fundam Clin Pharmacol 2000;14:301-19
84. Pascual J, El Berdei Y, Gomez-Sanchez JC. How many migraine patients need prolonged (>1 year) preventive treatment? Experience with topiramate. J Headache Pain 2007;8:90-3
85. Lainez MJ, Freitag FG, Pfeil J, et al. Time course of adverse events most commonly associated with topiramate for migraine prevention. Eur J Neurol 2007;14:900-6
86. Naegel S, Obermann M. Topiramate in the prevention and treatment of migraine: Efficacy, safety and patient preference. Neuropsychiatr Dis Treat 2010;6:17-28 An extensive review about topiramate in migraine prevention.
87. Ramadan NM. Current trends in migraine prophylaxis. Headache 2007;47(Suppl 1):S52-7
88. Silberstein S, Lipton R, Dodick D, et al. Topiramate treatment of chronic migraine: A randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 2009;49:1153-62
89. Packer AD, Naylor CD. Subgroups, treatments effects and baseline risk. Am Heart J 2000;139:952-61
90. Kaniecki R. Neuromodulators for migraine prevention. Headache 2008;48:586-600
91. Mulleners W, Chronicle E. Anticonvulsants in migraine prophylaxis: A Cochrane review. Cephalalgia 2008;28:585-97 An extensive review about anticonvulsants in migraine prophylaxis.
92. Krymchantowski AV, Jevoux CC. Topiramate vs divalproex sodium in the preventive treatment of migraine: A prospective "real-world" study. Headache 2011;51:554-8
93. Garattini S, Bertele V. Ethics in clinical research. J Hepatol 2009;51:792-7
94. Silberstein SD. Predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate. Cephalalgia 2010;30:1283
95. Brandes JL, Kudrow DB, Rothrock JF, et al. Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clin Proc 2006;81:1311-19
96. Silberstein SD, Loder E, Forde G, et al. The impact of migraine on daily activities: Effect of topiramate compared with placebo. Curr Med Res Opin 2006;22:1021-9
97. Freitag FG. The cycle of migraine: Patients' quality of life during and between migraine attacks. Clin Ther 2007;29:939-49
98. Dodick DW, Silberstein S, Saper J, et al. The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache 2007;47:1398-408
99. Lofland JH, Gagne JJ, Pizzi LT, et al. Impact of topiramate migraine prophylaxis on workplace productivity: Results from two US randomized, double-blind, placebo-controlled, multicenter trials. J Occup Environ Med 2007;49:252-7
100. Shinn AK, Greenfield SF. Topiramate in the treatment of substance-related disorders: A critical review of the literature. J Clin Psychiatry 2010;71:634-48 A through review of topiramate in the treatment of substance-related disorders.
101. Ferrari A, Cicero AF, Bertolini A, et al. Need for analgesics/drugs of abuse: A comparison between headache patients and addicts by the Leeds Dependence Questionnaire (LDQ). Cephalalgia 2006;26:187-93